Promimic AB (publ) (PRO.ST)
SEK 25.8
(6.61%)
SEK 25.8
(6.61%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -9.22 Million SEK | 41.95% |
| 2022 | -15.88 Million SEK | -4.61% |
| 2021 | -15.18 Million SEK | -7.05% |
| 2020 | -14.18 Million SEK | -22.15% |
| 2019 | -11.61 Million SEK | 22.5% |
| 2018 | -14.98 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.5 Million SEK | 0.11% |
| 2024 Q2 | -2.52 Million SEK | 27.86% |
| 2023 Q1 | -3.34 Million SEK | -3.4% |
| 2023 FY | -9.22 Million SEK | 41.95% |
| 2023 Q4 | -3.5 Million SEK | -281.7% |
| 2023 Q2 | -1.45 Million SEK | 56.42% |
| 2023 Q3 | -918 Thousand SEK | 36.99% |
| 2022 Q4 | -3.23 Million SEK | -5.41% |
| 2022 Q3 | -3.06 Million SEK | 31.42% |
| 2022 Q2 | -4.47 Million SEK | 12.57% |
| 2022 Q1 | -5.11 Million SEK | -29.33% |
| 2022 FY | -15.88 Million SEK | -4.61% |
| 2021 Q1 | -3.49 Million SEK | 0.0% |
| 2021 FY | -15.18 Million SEK | -7.05% |
| 2021 Q2 | -4.53 Million SEK | -29.81% |
| 2021 Q4 | -3.95 Million SEK | -23.59% |
| 2021 Q3 | -3.2 Million SEK | 29.47% |
| 2020 FY | -14.18 Million SEK | -22.15% |
| 2019 FY | -11.61 Million SEK | 22.5% |
| 2018 FY | -14.98 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 88.152% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 108.91% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 108.91% |
| Arcoma AB | 2.56 Million SEK | 459.672% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 93.336% |
| BICO Group AB (publ) | -835.7 Million SEK | 98.896% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 136.922% |
| CellaVision AB (publ) | 130.3 Million SEK | 107.077% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 88.442% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 68.403% |
| C-Rad AB (publ) | 35.52 Million SEK | 125.956% |
| Duearity AB (publ) | -26.19 Million SEK | 64.788% |
| Dignitana AB (publ) | -17.36 Million SEK | 46.887% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 90.272% |
| Getinge AB (publ) | 2.41 Billion SEK | 100.382% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 86.434% |
| Iconovo AB (publ) | -45.89 Million SEK | 79.906% |
| Integrum AB (publ) | 4.03 Million SEK | 328.693% |
| Luxbright AB (publ) | -25.37 Million SEK | 63.657% |
| Mentice AB (publ) | -2.81 Million SEK | -227.37% |
| OssDsign AB (publ) | -130.49 Million SEK | 92.933% |
| Paxman AB (publ) | 8.33 Million SEK | 210.708% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 94.235% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 83.409% |
| ScandiDos AB (publ) | -14.64 Million SEK | 37.038% |
| Sectra AB (publ) | 428.38 Million SEK | 102.153% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 84.53% |
| Senzime AB (publ) | -134.14 Million SEK | 93.126% |
| SpectraCure AB (publ) | -20.44 Million SEK | 54.885% |
| Stille AB | 26.64 Million SEK | 134.609% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 99.761% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 110.044% |